Lysogene and others partner to develop gene therapy for Fragile X

Lysogene S.A. (Euronext:LYS), SATT Conectus Alsace (Illkirch, France) and Institute of Genetics and Molecular and Cellular Biology (IGBMC) (Illkirch, France) partnered to develop a gene therapy to treat fragile X. SATT Conectus said it provided IP and invested over €390,000 ($478,277) into the project...